about
Partial agonism and antagonism of the ionotropic glutamate receptor iGLuR5: structures of the ligand-binding core in complex with domoic acid and 2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl]propionic acidIntersubunit Bridge Formation Governs Agonist Efficacy at Nicotinic Acetylcholine 4 2 Receptors: UNIQUE ROLE OF HALOGEN BONDING REVEALEDMolecular recognition of the neurotransmitter acetylcholine by an acetylcholine binding protein reveals determinants of binding to nicotinic acetylcholine receptorsSynthesis, pharmacology, and biostructural characterization of novel α4β2 nicotinic acetylcholine receptor agonistsAcetylcholine-Binding Protein Engineered to Mimic the α4-α4 Binding Pocket in α4β2 Nicotinic Acetylcholine Receptors Reveals Interface Specific Interactions Important for Binding and ActivityA mosaic of functional kainate receptors in hippocampal interneuronsStructural and functional studies of the modulator NS9283 reveal agonist-like mechanism of action at α4β2 nicotinic acetylcholine receptorsAugmentation of cognitive function by NS9283, a stoichiometry-dependent positive allosteric modulator of α2- and α4-containing nicotinic acetylcholine receptors.Synthesis and structure-activity relationships of 3,8-diazabicyclo[4.2.0]octane ligands, potent nicotinic acetylcholine receptor agonists.A-366833: a novel nicotinonitrile-substituted 3,6-diazabicyclo[3.2.0]-heptane alpha4beta2 nicotinic acetylcholine receptor selective agonist: Synthesis, analgesic efficacy and tolerability profile in animal models.Synthesis and structure-activity relationship studies of 3,6-diazabicyclo[3.2.0]heptanes as novel alpha4beta2 nicotinic acetylcholine receptor selective agonists.Comparison of the novel subtype-selective GABAA receptor-positive allosteric modulator NS11394 [3'-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile] with diazepam, zolpidem, bretazenil, and gaboxadol in rat models of inflammCharge selectivity of the Cys-loop family of ligand-gated ion channels.Ligand Binding at the 4-4 Agonist-Binding Site of the 42 nAChR Triggers Receptor Activation through a Pre-Activated Conformational State.Zolpidem is a potent stoichiometry-selective modulator of α1β3 GABAA receptors: evidence of a novel benzodiazepine site in the α1-α1 interface.Biophysical and pharmacological characterization of α6-containing nicotinic acetylcholine receptors expressed in HEK293 cells.In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107.Complementary three-dimensional quantitative structure-activity relationship modeling of binding affinity and functional potency: a study on alpha4beta2 nicotinic ligands.The rapid hydrolysis of chlordiazepoxide to demoxepam may affect the outcome of chronic osmotic minipump studies.Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels.Identification of a novel voltage-gated Na+ channel rNa(v)1.5a in the rat hippocampal progenitor stem cell line HiB5.Stable expression of the human large-conductance Ca2+-activated K+ channel alpha- and beta-subunits in HEK293 cells.Modulation of the Ca(2+)-dependent K+ channel, hslo, by the substituted diphenylurea NS 1608, paxilline and internal Ca2+.GABAA α5 subunit-containing receptors do not contribute to reversal of inflammatory-induced spinal sensitization as indicated by the unique selectivity profile of the GABAA receptor allosteric modulator NS16085.Two distinct allosteric binding sites at α4β2 nicotinic acetylcholine receptors revealed by NS206 and NS9283 give unique insights to binding activity-associated linkage at Cys-loop receptors.In vitro characterization of 5-carboxyl-2,4-di-benzamidobenzoic acid (NS3763), a noncompetitive antagonist of GLUK5 receptors.A pharmacological assessment of agonists and modulators at α4β2γ2 and α4β2δ GABAA receptors: The challenge in comparing apples with oranges.High and low GABA sensitivity α4β2δ GABAA receptors are expressed in Xenopus laevis oocytes with divergent stoichiometries.Concatenated nicotinic acetylcholine receptors: A gift or a curse?Thyrotropin internalization is directed by a highly conserved motif in the seventh transmembrane region of its receptor.The flavonoid, 2'-methoxy-6-methylflavone, affords neuroprotection following focal cerebral ischaemia.Engineered α4β2 nicotinic acetylcholine receptors as models for measuring agonist binding and effect at the orthosteric low-affinity α4-α4 interface.A pharmacological characterization of GABA, THIP and DS2 at binary α4β3 and β3δ receptors: GABA activates β3δ receptors via the β3(+)δ(-) interface.Delineation of the functional properties and the mechanism of action of TMPPAA, an allosteric agonist and positive allosteric modulator of 5-HT3 receptors.Unraveling the high- and low-sensitivity agonist responses of nicotinic acetylcholine receptors.NS383 Selectively Inhibits Acid-Sensing Ion Channels Containing 1a and 3 Subunits to Reverse Inflammatory and Neuropathic Hyperalgesia in Rats.Novel Approach for the Search for Chemical Scaffolds with Dual Activity with Acetylcholinesterase and the α7 Nicotinic Acetylcholine Receptor-A Perspective for the Treatment of Neurodegenerative DisordersGalantamine is not a positive allosteric modulator of human α4β2 or α7 nicotinic acetylcholine receptorsProbing the molecular basis for affinity/potency- and efficacy-based subtype-selectivity exhibited by benzodiazepine-site modulators at GABAA receptorsThe Delta-Subunit Selective GABA A Receptor Modulator, DS2, Improves Stroke Recovery via an Anti-inflammatory Mechanism
P50
Q27646152-1DC06082-F882-47F3-943B-983804EA1274Q27676179-9BF550D4-DFD5-41C0-B79E-B01531F3A634Q27682262-3BAB7F83-3E65-40BD-A795-D413C143F5C0Q27683619-2F0FB446-C434-4F2B-ABF2-E7A7239BC808Q27701563-DE1DA840-8FC8-4009-B5ED-EEDA5B9BF943Q28594162-85B4D909-9F51-475E-B5BD-F3299823C13BQ28655994-4718F79D-9A70-4E56-AF76-241B485175F3Q30449856-AF65622B-00AC-4889-B6F3-F68B38FAB18DQ34593176-7A21D9E4-24B8-4171-8310-7CDFA0A086EFQ34686974-BA7B5199-C80B-4CF6-A308-394FB6FCEFFAQ34700263-FBBD1D93-D2DD-4F4B-B3D6-7813D284F4FEQ34827132-CC20B274-AD28-42E3-873A-3E18F31A259BQ36016761-6F986789-9149-48E9-9B6A-63FBE12D590BQ36110375-C7F4C95A-C1FA-483D-B906-6AF11AA23FC0Q37040099-EA4A05CE-8FF6-4556-9A6A-CBD5EFA46F7AQ39070936-4C71ED14-566B-48AD-8C00-D5698CF4ECB7Q39700093-025981F2-58FA-419D-895C-CAAA83774EB9Q39870413-6EC4BF7C-F763-4EF2-9AFA-5C3C69FFF5A3Q40369026-A9549717-27E4-432E-8133-CEB5957971D7Q40438135-EC05688B-1F20-4B07-B521-45AA340AB8ABQ40770659-C7E038AA-4065-4F42-B6F8-90A14A30091BQ41084534-AC0FFBEB-405C-49EA-B50A-6AE3D9AC493EQ41244780-E64C41D2-62EA-47CB-86FF-7CFD93D85D70Q41646441-7783491A-0456-4E11-B9AF-C7F34BBB3F23Q42123087-12AF4871-BD9F-4932-85E3-5A109C5C3178Q44777504-7363E8C8-C174-4BB9-ADC0-704E9683C66FQ47430984-331D2658-0D7B-433C-AE47-E12CEFDA559CQ47602713-FEB5DD10-FC10-48D0-B664-C3B11C1D791EQ47703691-365C56D1-2D48-48CA-87EA-D7562D6FCB95Q47773632-2DEB66E3-9D2F-431C-91D9-A75ED4D63897Q47835541-FA5D64BC-0514-4EC2-AF75-891D4FA67A0AQ48373654-ED82D858-2580-4BE4-8AC8-88C07603D54BQ48550453-87D3E821-9EB3-47C4-8AF7-741A76AA13D9Q48553072-83003D1E-7CCA-4474-A260-B37027F75DFAQ48667658-0CCF99FF-AE8E-480E-8986-1C6C2538393BQ51739932-147F7028-3AE7-4B71-B55C-4FDF8E8E4940Q64268861-39E289A3-C2A5-4347-AEFD-E052306837E1Q88399016-0C23453B-B7B2-488E-B501-A2DAD88EDD52Q91018846-28BDEBB9-667D-4FF6-9E29-7F733826746AQ91315975-89E5A29F-D0A0-4222-8144-6ECE0E28BC11
P50
description
researcher
@en
wetenschapper
@nl
name
Joergen Philip Kiaer Ahring
@en
Joergen Philip Kiaer Ahring
@nl
Joergen Philip Kiaer Ahring
@pl
type
label
Joergen Philip Kiaer Ahring
@en
Joergen Philip Kiaer Ahring
@nl
Joergen Philip Kiaer Ahring
@pl
altLabel
P K Ahring
@en
prefLabel
Joergen Philip Kiaer Ahring
@en
Joergen Philip Kiaer Ahring
@nl
Joergen Philip Kiaer Ahring
@pl
P106
P31
P496
0000-0003-1807-3331